about
Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosisNon-alcoholic fatty liver disease: need for a balanced nutritional source4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content.Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New TreatmentsLycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis modelModern approach to the clinical management of non-alcoholic fatty liver diseaseEvaluation of the protective effect of silibinin against diazinon induced hepatotoxicity and free-radical damage in rat liver.Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD).Hepatoprotective effect of silymarin.Silymarin and diabetic nephropathyThe role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Non-alcoholic Fatty Liver Disease: Beneficial Effects of Flavonoids.Effect of sılymarın on oxıdatıve stress and lıver hıstopathology ın experımental obstructıve jaundıce model.Evaluation of the protective effect of silibinin in rats with liver damage caused by itraconazole.Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis.Self-nanoemulsifying drug delivery systems ameliorate the oral delivery of silymarin in rats with Roux-en-Y gastric bypass surgeryProtective effect of rutin in comparison to silymarin against induced hepatotoxicity in rats.Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease.Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models.The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials.In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.Electrochemical Determination of Capsaicin and Silymarin Using a Glassy Carbon Electrode Modified by Gold Nanoparticle Decorated Multiwalled Carbon NanotubesPotential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD
P2860
Q28084150-F8BF14E0-F3CD-401A-B9FA-6FB1C40E1173Q28248994-9A03E219-507B-4A19-98B9-365FCB723452Q30412771-45188920-CC00-4F56-8FDC-C322F55592A0Q30422374-418044AC-65E6-44F2-8FC6-CA834FDDCBF4Q33616887-BF530650-9ED7-496E-AB46-AFE0AAA576ABQ33851125-F6C9D6F6-0386-4D23-8A73-53C246026ECEQ33886923-AE6A8A96-C7D6-436E-989B-B02D9B760D7EQ35645012-E4F9F992-2CC2-497D-A886-2100A84D0C5EQ36841336-FF51F48B-119E-4870-8368-16D259A673AFQ37646391-8D8030E1-7124-4148-82D3-DBFA0DCF5CE5Q38262135-8EEE2632-5B1D-4B40-A85C-3B2141A72E59Q38725130-C8410191-74DF-44A3-92B8-3D609ABA418EQ38782562-B25541E8-E184-4B88-923B-15C9D39958F3Q38866384-DD0EEC54-615B-484D-9B3E-89D4819F741AQ39027008-9A4E00FB-753E-455B-9853-6B008A4DDF07Q41662672-8D4555E1-BCE2-4EC7-9DB1-293F7BA89A77Q41817046-CC9CF533-446A-4776-AF0F-A571DE54F5CDQ41969540-D236772B-D502-4D75-A0F7-67F6F8D7D339Q42322587-C2CA1C06-7A72-49D2-84A7-CA40C1194445Q44339679-380B7B9F-9B95-4CBD-B7AB-25836821EA8BQ46241318-8B85C5C1-C2B4-4295-8ECE-1B8A30B475FBQ47132791-2070467D-192D-4B47-A5AC-2DF2876F9AC9Q48103883-2E0B23D7-D5D0-4B15-B506-9C3062AF07DAQ48152092-0D3FD333-BBDA-49C3-9B1F-B9FFE88FA7CEQ58128419-736C9A23-410C-495E-8C7C-5E93F7466911Q58753073-71523671-64E5-43DD-8DB2-85E5CD5CF901
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Silymarin in non alcoholic fatty liver disease.
@ast
Silymarin in non alcoholic fatty liver disease.
@en
Silymarin in non alcoholic fatty liver disease.
@nl
type
label
Silymarin in non alcoholic fatty liver disease.
@ast
Silymarin in non alcoholic fatty liver disease.
@en
Silymarin in non alcoholic fatty liver disease.
@nl
prefLabel
Silymarin in non alcoholic fatty liver disease.
@ast
Silymarin in non alcoholic fatty liver disease.
@en
Silymarin in non alcoholic fatty liver disease.
@nl
P2093
P2860
P356
P1476
Silymarin in non alcoholic fatty liver disease.
@en
P2093
Anna Scognamiglio
Federico Cacciapuoti
Fulvio Cacciapuoti
Raffaele Forte
Rossella Palumbo
P2860
P304
P356
10.4254/WJH.V5.I3.109
P577
2013-03-01T00:00:00Z